Previous 10 | Next 10 |
PLANO, Texas, June 07, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that management will participate in a virtual Fireside chat and...
Are These Trending Biotech Stocks On Your June 2021 Watchlist? Biotech stocks are one of the most popular stocks in the stock market today . Now, why is that so? Well, largely because most investors are enticed by the idea of a huge profit trade and this sector fits the bill. Of...
CNS Pharmaceuticals (NASDAQ: CNSP) is on track to begin a potentially pivotal Phase 2 trial during the second quarter of 2021. This trial of CNSP’s lead drug candidate, Berubicin, in the treatment of glioblastoma multiforme (“GBM”) is currently planned to include up to...
Top Health Care Stocks To Watch In The Stock Market This Week Health care stocks are one of the most significant sectors in the stock market . In fact, health care was a defensive play even before the pandemic. But with more people infected with COVID-19 facing long-term health ...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “ Reata Pharmaceuticals, Inc. Surges as FDA Requests Preliminary Drug Meeting ” Reata Pharmaceuticals, Inc. (NASDAQ: RETA) surged over 13% in prem...
As of midafternoon Wednesday, shares of Reata Pharmaceuticals (NASDAQ: RETA) were up by a whopping 22.7%. That was on the back of very promising news on the regulatory front for the clinical-stage biotech. Reata disclosed that it received a notice from the Food and Drug Administ...
The U.S. Food and Drug Administration (FDA) sent a communication to Reata Pharmaceuticals Inc. ( NASDAQ: RETA ) on Wednesday, recommending that it submits a new request for a pre-NDA meeting. The pharmaceutical company’s shares gained 20% in the morning session. Reata had...
Gainers: MoSys (MOSY) +32%.Lianluo Smart (LLIT) +30%.Advaxis (ADXS) +27%.Reata Pharmaceuticals (RETA) +22%.LifeMD (LFMD) +18%.Taitron Components (TAIT) +17%.FreightCar America (RAIL) +14%.Transcat (TRNS) +14%.PureCycle Technologies (PCT) +14%.Aehr Test Systems (AEHR) +12%.Losers:...
Gainers: Reata Pharmaceuticals (RETA) +20%, LifeMD (LFMD) +13%, Eloxx Pharmaceuticals (ELOX) +10%, Cerecor (CERC) +10%, Biofrontera (BFRA) +7%.Losers: Onconova Therapeutics (ONTX) -23%, Iovance Biotherapeutics (IOVA) -18%,&...
Lixte Biotechnology Holdings (LIXT) +21%.LightPath Technologies (LPTH) +16%.Reata Pharmaceuticals (RETA) +14% as FDA requested pre-NDA meeting for Omaveloxolone.Verona Pharma (VRNA) +10%.Cerecor (CERC) +6%.TAT Technologies (TATT) +5% on partnership with Lufthansa Technik Shenzhen ...
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (N...